Factor Therapeutics Ltd (FTT)

FTT Chart

vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Advanced

Show News Mov Avgs 9-day 10-day 20-day 30-day 50-day 100-day 150-day 200-day Mov Avgs 9-day 21-day 30-day 200-day Simple Exponential Weighted Simple Exponential Weighted vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Mov Avgs 10-day 20-day 30-day 50-day 100-day 150-day 200-day 9/21 Cross 10/30 Cross Golden Cross Vol RSI BB

Day 3m 6m 1yr 5yr 10yr

FTT's Principal Activity is the identification and diligence of potential new business opportunities for the Company.

Announcements

Company Overview

Dividend History

Directors & Management

Name	Title	Since	Bio
Dr David Lionel Brookes	Non-Executive Director,Non-Executive Chairman	Apr 2019	Dr David Lionel Brookes Non-Executive Director,Non-Executive Chairman Dr Brookes has experience in the health and biotechnology industries and is currently a Non-Executive director of Anatara Ltd (ASX:ANR) and TALi Digital Limited (ASX:TD1). He has previously been a director of several other ASX listed biotechnology companies, most recently as the Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc in June 2018. Until its acquisition in January 2021, Dr Brookes was Non-Executive Chairman of the Better Medical Group, and maintains roles as a clinician and a biotechnology industry consultant. He is Member of Risk Management Committee.
Mr John Michailidis	Non-Executive Director	Feb 2017	Mr John Michailidis Non-Executive Director Mr Michailidis is currently the Managing Director for TEVA Australia/NZ and brings over 30 years of commercial pharmaceutical experience to Factor, most recently as Managing Director for TEVA, Australia and New Zealand. His career has ranged from global franchise and regional executive leadership roles with F. Hoffman - La Roche (Roche) to CEO experience with growth-stage biopharmaceutical companies, such as AviPep and Orphan Australia (acquired by Sigma). He is Chair of Risk Management Committee.
Ms Melanie Farris	Company Secretary	Sep 2016
Dr Christian Peter Behrenbruch	Non-Executive Director	Oct 2015	Dr Christian Peter Behrenbruch Non-Executive Director Dr Behrenbruch has over 15 years of C-level leadership experience in the medtech, biotechnology and healthcare IT space, and has significant experience as a director of commercial and non-profit organisations. His former CEO/Director-level appointments include Mirada Solutions (now Siemens Plc), Fibron Technologies and ImaginAb, Inc. He is a former director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (now Adaptix), Cell Therapies P/L (Peter MacCallum Cancer Centre) and the Oncidium Foundation. He is currently the Managing Director and CEO of Telix Pharmaceuticals Limited (ASX:TLX), Chairman of Monash Engineering and IT Foundation Board and is a Professorial Fellow at Monash University.

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
19/04/18	Cherrell Hirst	Issued	474,830	$0.04	$18,993	Rights issue
19/04/18	Christian Behrenbruch	Issued	408,164	$0.04	$16,327	Rights issue
19/04/18	John Michailidis	Issued	527,432	$0.04	$21,097	Rights issue

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
John Michailidis	31/12/2020	N/A	527,432	1,000,000	N/A
Christian Behrenbruch	31/12/2020	N/A	3,265,306	3,000,000	N/A
David Brookes	31/12/2020	2,500,000	10,300,000	N/A	N/A

Show All

Top 20 Shareholders About the Data

Name	Shares	Capital
Calama Holdings Pty Ltd	40,000,000	3.84%
GP Securities Pty Ltd	28,607,989	2.74%
Citicorp Nominees Pty Limited	24,261,921	2.33%
Yelwac Pty Ltd	22,594,216	2.17%
Symington Pty Ltd	19,700,000	1.89%
HSBC Custody Nominees (Australia) Limited	16,314,861	1.56%
Mr Jules Christian Wilson	15,099,502	1.45%
Dr Alok Jhamb	15,000,000	1.44%
Mr Francis Xavier Parnis & Mrs Sally Jane Parnis	14,554,598	1.40%
Mr Michael Andrew Whiting & Mrs Tracey Anne Whiting	12,876,085	1.23%
Nurragi Investments Pty Ltd	12,850,000	1.23%
Mr Kevin John Day	12,500,000	1.20%
Mr Konstandinos Emmanouil	12,000,000	1.15%
Harold Cripps Holdings Pty Ltd	11,623,027	1.11%
Mr Anthony Bratton	10,986,115	1.05%
Jetosea Pty Ltd	10,000,000	0.96%
Aglub Investments Pty Ltd	9,945,731	0.95%
Ms Pharoth San & Mr Kaden San	9,500,000	0.91%
Gattenside Pty Ltd	9,033,037	0.87%
Queensland University Of Technology	8,087,010	0.78%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.003	30 June
2019	$0.004	28 June
2018	$0.047	29 June
2017	$0.062	28 June
2016	$0.034	28 June

FTT Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.